Presents a" balance" theoretical hypothesis which argues that the self-concept of an individual
in relation to the task at hand is a determinant of the outcome he will seek to attain and …

Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

Immunotherapy has now been clinically validated as an effective treatment for many cancers.
There is tremendous potential for synergistic combinations of immunotherapy agents and …

Background In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte–associated
antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody …

Background Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T
cells, can overcome immune resistance. We assessed the antitumor activity and safety of …

Background Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of
its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host's immune …

Purpose Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells,
may suppress antitumor immunity. This phase I study sought to determine the safety and …

The immune system influences the fate of developing cancers by not only functioning as a
tumour promoter that facilitates cellular transformation, promotes tumour growth and sculpts …

Inhibitory receptors on immune cells are pivotal regulators of immune escape in cancer.
Among these inhibitory receptors, CTLA-4 (targeted clinically by ipilimumab) serves as a …

A large number of cancer-associated gene products evoke immune recognition, but host
reactions rarely impede disease progression. The weak immunogenicity of nascent tumors …